Drug intelligence / Profile preview

GLY-102

Development stage: Preclinical
Lead developer: Glycan Therapeutics
Modality: Microbiome-Derived Products → Microbiome Therapeutics

Overview

GLY-102 is a synthetic heparin-derived oligosaccharide currently in preclinical development by Glycan Therapeutics. It is designed as an anticoagulant for the prophylaxis of deep vein thrombosis (DVT). The drug exerts its therapeutic effect through the selective inhibition of Factor Xa, a key serine protease in the coagulation cascade that mediates the conversion of prothrombin to thrombin. By utilizing chemoenzymatic synthesis to produce a defined oligosaccharide structure, GLY-102 aims to provide a more predictable pharmacological profile and improved safety compared to traditional, heterogeneous heparin products derived from animal sources.

Targets

ATIII (Antithrombin III)F10 (Factor Xa)

Beyond the preview

Go deeper on GLY-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLY-102.

Explore the full profile